Dr. Yoshinori Matsumoto is a physician-scientist and Research Associate Professor at the Department of Rheumatology, Okayama University Hospital, Japan. He specializes in translational research at the interface of immunology, bone metabolism, and inflammation, with a particular focus on 3BP2-mediated signaling and its pathological roles in autoimmune and inflammatory diseases. After completing his clinical training in internal medicine and rheumatology in Japan, Dr. Matsumoto conducted post-doctoral research for over five years at the University of Toronto under Professor Robert Rottapel, where he discovered key mechanisms linking 3BP2 to autoinflammatory bone disease (cherubism). Upon returning to Japan, he established his independent research group at Okayama University, where he integrates molecular immunology, single-cell multi-omics, and in-vivo disease models to identify novel therapeutic targets. His laboratory is developing innovative therapeutic modalities for immune-mediated disorders such as systemic lupus erythematosus. Dr. Matsumoto has authored numerous peer-reviewed papers, including four publications in The Journal of Clinical Investigation (JCI), which have significantly advanced the understanding of 3BP2 signaling and its translational implications. His research achievements have been recognized by multiple awards and national funding programs, and he is currently leading a startup-oriented project to develop first-in-class therapeutics.